Sort By

LanthaScreen™ Tb-anti-ERK2 [pThr185/pTyr187] Antibody

A part of the MAPK Pathway, ERK2 is phosphorylated at Thr185 and Tyr187 by the mitogen-activated protein kinase kinases 2 (MAP2K2) .
For use in combination with the LanthaScreen® ERK2 A375 cell line (K1798) to evaluate inhibitors in medium to high throughput screening applications.

ERK1/ERK2 Antibody (3HCLC), ABfinity™ Rabbit Oligoclonal (Invitrogen™)

ERK1/ERK2 Oligoclonal Antibody for Western Blot, ChIP

ERK1/ERK2 Antibody (6HCLC), ABfinity™ Rabbit Oligoclonal (Invitrogen™)

ERK1/ERK2 Oligoclonal Antibody for Western Blot, ChIP

ERK2 Polyclonal Antibody (Invitrogen™)

ERK2 Polyclonal Antibody for Western Blot, IHC, Flow

ERK2 Polyclonal Antibody (Invitrogen™)

ERK2 Polyclonal Antibody for Western Blot

ERK2 Polyclonal Antibody (Invitrogen™)

ERK2 Polyclonal Antibody for Western Blot, IHC (P)

ERK2 Polyclonal Antibody (Invitrogen™)

ERK2 Polyclonal Antibody for Western Blot, IHC

ERK2 Polyclonal Antibody (Invitrogen™)

ERK2 Polyclonal Antibody for Western Blot, IHC (P), IP, ChIP

ERK2 Polyclonal Antibody (Invitrogen™)

ERK2 Polyclonal Antibody for IHC (P)

ERK2 Polyclonal Antibody (Invitrogen™)

ERK2 Polyclonal Antibody for Western Blot

ERK2 Monoclonal Antibody (1A1) (Invitrogen™)

ERK2 Monoclonal Antibody for Western Blot, IP

MAPK1 (ERK2) Recombinant Human Protein, Inactive

MAPK1 (ERK2) is a serine⁄threonine kinase that acts as an important activator of p90 RSK, MSK, ELK1, and Stat3, and is involved in the MAPK pathway.

MAPK1 (ERK2) Recombinant Human Protein

MAPK1 (ERK2) is a serine⁄threonine kinase that acts as an important activator of p90 RSK, MSK, ELK1, and Stat3, and is involved in the MAPK pathway.

AKT/ERK/p70 S6K Activation Multispecies InstantOne™ ELISA Kit (Invitrogen™)

AKT/ERK/p70 S6K Activation Multispecies InstantOne™ ELISA Kit for ELISA

CellSensor™ AP-1-bla ME-180 Cell Line

The CellSensor® AP-1-bla ME-180 Cell Line contains a beta-lactamase reporter gene under control of the AP-1 response element stably integrated into ME-180 cells. The cell line was created through FACS sorting of cells responsive to stimulation of the AP-1 pathway with Epidermal Growth Factor (EGF). This cell line was validated for DMSO tolerance, stimulant incubation time, substrate loading conditions, Z' and EC50 concentration of Epidermal Growth Factor. The AP-1-bla ME-180 Cell Line responds to agonist treatment as expected from the literature and can be adapted for high-throughput screening for agonists or antagonists of the AP-1 pathway with compound libraries. Candidate drugs can also be tested for dose response against this cell line. Academic and non-profit customers, please inquire for special pricing.